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Clinical practice guidelines of remote ischemic 
conditioning for the management of cerebrovascular 
diseases
Xunming Ji1, Wenbo Zhao2,3, Johannes Boltze4, Sijie Li3, Ran Meng2, Yuan Wang2, Gregory J Bix5, Cesar 
V Borlongan6, Jeffrey M Gidday7, Sebastian Koch8, John C Quindry9, Rajiv R Ratan10, Kristin Veighey11,12, 
Guohua Xi13, Giuseppe Pignataro14, David C Hess15, and Derek J Hausenloy16,17,18,19,20,21
Remote ischemic conditioning (RIC) using transient limb ischemia and reperfusion has been shown 
in small clinical studies to reduce myocardial injury and infarction in cardiac patients, although larger 
clinical outcome studies have been neutral. Experimental and emerging clinical studies have also 
reported beneficial effects of limb RIC in a number of different settings of cerebrovascular disease 
including stroke (ischemic and hemorrhagic), carotid artery stenosis, intracranial artery stenosis, 
aneurysms, small vessel disease, and vascular cognitive impairment. Although limb RIC has many 
advantages, in that it is non-invasive, easy to administer, relatively innocuous, cost-effective, has few 
or no contraindications, and may be deployed under various circumstances (e.g., home, ambulance, 
and hospital), several questions remain regarding its clinical application for cerebrovascular disease. 
Therefore, in this document, we aim to provide practicing clinicians with a coherent synthesis of the 
latest scientific evidence, and we propose several recommendations to help facilitate the clinical 
application of limb RIC for the management of cerebrovascular disease. 
Keywords: clinical practice guidelines; remote ischemic conditioning; preconditioning; cerebrovascular 
diseases; stroke; cognitive impairment
1Department of Neurosurgery, Xuanwu Hospital, Capital Medical University, Beijing, China. 2Department of Neurology, 
Xuanwu Hospital, Capital Medical University, Beijing, China. 3Beijing Key Laboratory of Hypoxic Conditioning 
Translational Medicine, Xuanwu Hospital, Capital Medical University, Beijing, China. 4School of Life Sciences, University 
of Warwick, Coventry CV4 7AL, United Kingdom. 5Clinical Neuroscience Research Center, Tulane University School of 
Medicine, New Orleans, LA USA. 6Department of Neurosurgery and Brain Repair, University of South Florida Morsani 
College of Medicine, Tampa, FL USA. 7Departments of Ophthalmology, Physiology, and Neuroscience Louisiana State 
University School of Medicine, New Orleans, LA. 8Department of Neurology, University of Miami Miller School of 
Medicine, Miami, FL, USA. 9School of Integrative Physiology and Athletic Training, College of Health Professions and 
Biomedical Sciences University of Montana, Missoula, MT. 10Burke Medical Research Institute, White Plains, NY USA
11Wessex Kidney Centre, Queen Alexandra Hospital, Portsmouth, UK. 12Research & Development, University Hospital 
Southampton NHS Foundation Trust, Southampton, UK. 13Department of Neurosurgery, University of Michigan, Ann 
Arbor, MI USA. 14Department of Neuroscience, School of Medicine “Federico II” University of Naples, Napoli, Italy. 
15Medical College of Georgia, Augusta University, Augusta, GA USA. 16Cardiovascular & Metabolic Disorders Program, 
Duke-National University of Singapore Medical School, Singapore. 17National Heart Research Institute Singapore, 
National Heart Centre, Singapore. 18Yong Loo Lin School of Medicine, National University Singapore, Singapore. 
19The Hatter Cardiovascular Institute, University College London, London, UK. 20The National Institute of Health 
Research University College London Hospitals Biomedical Research Centre, Research & Development, London, UK. 
21Department of Cardiology, Barts Heart Centre, St Bartholomew’s Hospital, London, UK.
The authors above worked on behalf of the RICA Working Group.
Correspondence should be addressed to Dr. Xunming Ji (jixm@ccmu.edu.cn).
On recommendation for clinical practice by the American Association of Conditioning Medicine
REVIEW ARTICLE
Conditioning Medicine 2019 | www.conditionmed.org
Conditioning Medicine | 2019, 2(5):225-241
226
Introduction
Cerebrovascular disease refers to a wide spectrum of disorders 
of the brain vasculature, including stroke (ischemic and 
hemorrhagic), carotid artery stenosis, intracranial artery 
stenosis, aneurysms, small vessel disease, and vascular 
cognitive impairment (Fisher, 2010; Rea, 2015; Smith et al., 
2017; Absher et al., 2018). Currently, cerebrovascular disease 
is the second most common cause of mortality worldwide and 
the most common cause of long-term disability (Lozano et al., 
2012; Vos et al., 2017). In some regions of the world, it has 
exceeded ischemic heart disease as the leading cause of death 
(Roth et al., 2015a). Consequently, cerebrovascular disease 
is responsible for great disease burden worldwide (Hay et al., 
2017; Vos et al., 2017; Wang et al., 2017a). In the past four 
decades, the diagnosis and treatment of cerebrovascular disease 
has advanced significantly. Furthermore, studies have revealed 
that approximately 90% of cerebrovascular disease cases are 
preventable with medications, surgery, and modifications 
of risk factors (O'Donnell et al., 2010; Caprio and Sorond, 
2019). Despite improvements in preventive and therapeutic 
measures, their effects on cerebrovascular disease remain far 
below expectation. Furthermore, many of the treatments incur 
significant costs and are associated with serious complications 
(Rose, 1981; Feigin et al., 2015b; Benjamin et al., 2019). Thus, 
cerebrovascular disease burden continues to increase worldwide 
(Feigin et al., 2015a; Roth et al., 2015b). These collective issues 
have created an urgent, unmet need for new effective and safe 
strategies for the management of cerebrovascular disease.
Remote ischemic conditioning
Remote ischemic conditioning (RIC) has evolved from 
classic ischemic preconditioning (Murry et al., 1986), and 
is a protective systemic strategy whereby several cycles of 
brief non-lethal ischemia followed by reperfusion in an organ 
or tissue confer protection against subsequent, more severe 
lethal ischemia in distant vital organs (e.g., heart and brain) 
(Przyklenk et al., 1993). After decades of methodological 
evolution, RIC is now generally simply performed on the arms 
or legs using blood pressure cuffs inflated to induce transient 
ischemia and reperfusion (Hess et al., 2015; Hausenloy et al., 
2016; Hausenloy and Yellon, 2016). Based on investigations of 
coronary heart disease, RIC has now been widely investigated 
in many other organs, including brain, kidney, lung, liver, and 
the gastrointestinal tract (Holscher et al., 2007; Crowley and 
McIntyre, 2013; Li et al., 2014; Chu et al., 2015; Hausenloy 
and Yellon, 2016; Garcia-de-la-Asuncion et al., 2017; Ghelfi 
et al., 2017; Zhao et al., 2019). As cerebrovascular disease and 
coronary heart disease share many common pathophysiological 
mechanisms, an increasing number of RIC studies have focused 
on cerebrovascular disease management. To date, RIC has been 
shown to increase cerebral tolerance to ischemic injury, reduce 
the risk of cerebral infarction, improve cerebral perfusion status, 
and promote the formation of cerebral collaterals in patients 
with ischemic stroke (Meng et al., 2012; Hougaard et al., 2014; 
Meng et al., 2017b). Furthermore, RIC also can be safely used 
in patients with intracranial hemorrhage and can improve their 
functional outcomes (Koch et al., 2011; Gonzalez et al., 2014; 
Laiwalla et al., 2016b). As a non-invasive, safe strategy, RIC 
has paved the way for exciting new prospects in the broader 
management of both ischemic and hemorrhagic cerebrovascular 
disease (Hess et al., 2015; Zhao et al., 2019). 
Why it is important to develop these clinical practice 
guidelines
Based on current studies, RIC is non-invasive, easy to 
administer,  innocuous, cost-effective,  has few or no 
contraindications, and may be deployed under various 
circumstances (e.g., home, ambulance, and hospital) (Zhao 
et al., 2019). However, many questions regarding the use of 
RIC for cerebrovascular disease management have been left 
unanswered, such as: 1) “How many types of RICs exist?; 2) 
How might RIC work?; 3) Which subtypes of cerebrovascular 
disease patients should RIC be implemented, and how?; 4) 
What should be done prior to the initiation of RIC treatment to 
ensure its safety?; 5) Are there any contraindications or adverse 
events related to RIC?; and 6) Which device should be used 
to perform RIC procedures? These collective questions might 
hinder the broad acceptance of RIC by clinicians, investigators, 
and patients as an effective strategy for the management of 
cerebrovascular disease. 
This document aims to provide practicing clinicians 
with a coherent synthesis of the latest research and several 
recommendations to facilitate the clinical application of RIC for 
the management of cerebrovascular disease. Because the clinical 
questions surrounding the management of cerebrovascular 
disease with RIC can be broad and beyond the scope of a single 
document, this panel of experts opted to narrow the focus of the 
guidelines to critical issues of the utmost relevance to clinicians, 
patients, and caregivers.
Methods
Committee composition
T h e  g u i d e l i n e  d e v e l o p m e n t  p a n e l  e n c o m p a s s e d 
multidisciplinary specialists, including neuroscientists, 
stroke neurologists, cognitive neurologists, neurosurgeons, 
neuroradiologists, and cardiologists. Three patients who 
received RIC treatment and their primary caregivers also 
provided insightful suggestions used to formulate the 
clinical questions. Beside suggestions from the panel of 
practicing clinicians, investigators, patients, and caregivers, 
the panel also employed the GRADE approach (Grading of 
Recommendations, Assessment, Development, and Evaluation) 
to formulate clinical questions II through VI, to summarize the 
relevant evidence, and to develop recommendations for clinical 
practice. Full methodological details and tables supporting 
the recommendations for these five clinical questions can be 
found in the online supplement. To address clinical question I, 
the panel of experts identified both animal and clinical studies, 
and subsequently synthesized the latest evidence. In addition, 
instead of a systematic literature review, the expert panel 
performed a narrative review of the evidence to identify the best 
answers to clinical questions VII and XI. For clinical questions 
VIII, IX, and X, recommendations were based on a consensus 
of expert opinion, as there were no specific studies investigating 
those questions.
Clinical question I: How many subtypes of RIC are there 
and how might they work?
Subtypes of RIC
The first RIC report was published by Przyklenk, Whittaker, 
and colleagues in 1993. They reported the novel finding that 
several brief periods of ischemia followed by reperfusion 
applied to the myocardium supplied by one coronary branch 
conferred resistance against lethal ischemia/reperfusion 
to another part of the myocardium supplied by a different 
coronary branch and reduced the final infarct size (Przyklenk 
et al., 1993). This intriguing phenomenon was named 
“Remote Ischemic Preconditioning”. In 2003, Dr. Zhiqing 
Zhao from Vinten-Johansen’s group first reported “Ischemic 
Postconditioning,” based on the attenuation of reperfusion 
injury with a conditioning procedure commenced only at the 
start of reperfusion in a canine model of myocardial infarction 
(Zhao et al., 2003). Next, in 2005, Vinten-Johansen’s group 
reported that brief renal ischemia and reperfusion applied 
before coronary artery reperfusion reduced myocardial infarct 
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size by activation of adenosine receptors, and this endogenous 
protection was called “Remote Postconditioning” (Kerendi et 
al., 2005). However, the “Remote Postconditioning” reported 
in this particular study is now defined as “Remote Ischemic 
Perconditioning”, as the conditioning stimulus was applied 
during the index myocardial ischemic episode. Li and colleagues 
reported in 2006 that limb ischemic postconditioning protects 
the myocardium from ischemia-reperfusion injury (Li et al., 
2006), providing the most promising type of postconditioning 
for clinical application to date. In 2007, Andreka et al., (2007) 
reported that remote ischemic postconditioning induced by four 
5 minutes cycles of blood pressure cuff inflation applied to the 
lower limb immediately after reperfusion significantly reduced 
myocardial infarct size; this was the first time that the term 
“Remote Ischemic Postconditioning” was formally used. In the 
same year, Schmidt and colleagues conducted an animal study 
to test the protective effects of ischemic preconditioning when 
it was administered during ischemia and before reperfusion (i.e., 
perconditioning) (Schmidt et al., 2007). Based on this study, the 
existence of remote ischemic perconditioning was first shown 
and demonstrated to be effective. 
Currently, the term “remote ischemic conditioning” is 
often employed to encompass remote ischemic pre-, per-, and 
postconditioning. These three subtypes of RIC were proposed 
based on models of myocardial ischemia/reperfusion. Remote 
ischemic preconditioning is applied before the index ischemia, 
remote ischemic perconditioning is applied after ischemia but 
before reperfusion of the index ischemia, and remote ischemic 
postconditioning is applied after reperfusion of the index 
ischemia (Hess et al., 2015). In clinical practice, the terms can 
be used accurately in acute ischemic stroke patients treated with 
endovascular thrombectomy and in acute myocardial infarction 
patients treated with percutaneous coronary intervention. In 
other patient populations, however, it may be difficult to clearly 
distinguish between subtypes of RIC. Therefore, the term 
Remote Ischemic Conditioning, while not necessarily precise, 
appears to be the best compromise. 
Mechanisms underlying RIC
RIC has been widely investigated in both animal and human 
studies, but the precise mechanisms through which it exerts 
protection against ischemic insults in a distant organ or tissue is 
currently unclear. The mechanisms underlying RIC have been 
studied for nearly 30 years, and most of the published literature 
on RIC is related to the heart. Based on this large body of work, 
the potential mechanisms underlying RIC can be classified into 
four categories—humoral, neural, immune, and inflammatory 
pathways. 
It is known that a period of reperfusion of the remote 
conditioned organ or tissue is essential for RIC, suggesting 
transportation of humoral/diffusible factors produced during the 
ischemic period to distant organs (Gho et al., 1996). In addition, 
the use of a ganglion blocker (hexamethonium) (Gho et al., 
1996), resection of the neural innervation of the limb (Lim et 
al., 2010), and genetic inhibition of preganglionic vagal neurons 
in the brainstem (Mastitskaya et al., 2012), have all been shown 
to abrogate the protection of RIC. These findings indicate that 
an intact neural pathway is also required for RIC. Furthermore, 
stimulation of neural pathways in the remotely conditioned 
organ and tissue may be elicited by local production of 
autacoids, such as adenosine (Steensrud et al., 2010), bradykinin 
(Schoemaker and van Heijningen, 2000), calcitonin gene-related 
peptide (Li et al., 1996), and others. Although neurohumoral 
factors may initiate the cascade of conditioning and produce 
a preconditioning-like effect, it also appears that non-specific 
innate immunity may be instrumental in ischemic conditioning. 
The key elements of the latter process are gene expression, 
leukocytes, and mitochondria. Several animal studies have 
examined the effects of RIC on inflammatory responses and 
observed that the pro-inflammatory response is inhibited while 
a favorable profile of anti-inflammatory and anti-apoptotic gene 
transcription is engaged (Tsang et al., 2005; Fujita et al., 2007; 
Shi and Vinten-Johansen, 2012). 
Importantly, studies have found that RIC improves 
collaterals and cerebral blood flow, which may play important 
roles in reducing cerebral damage. Experimental studies 
have found that RIC promoted new collateral formation and 
angiogenesis and augmented collateral flow, and this has been 
demonstrated to be why RIC reduces cerebral damage and 
improve neurological outcomes (Ma et al., 2017; Kitagawa et 
al., 2018; Zhang et al., 2019). A clinical study also found that in 
patients with symptomatic intracranial atherosclerotic stenosis, 
long-term RIC appears to accelerate cerebral collateral opening 
and vascular remodeling, which may play roles in preventing 
recurrent ischemic stroke (Meng et al., 2017a). Additionally, 
RIC has been found to improve cerebral blood flow in both 
ischemic and hemorrhagic stroke models (Laiwalla et al., 
2016b; Ren et al., 2018), and this phenomenon has been further 
demonstrated in patients with ischemic cerebrovascular diseases 
(Meng et al., 2012).
In summary, the mechanisms that mediate RIC are 
multifactorial, and the precise interrelationship between 
various signals is not yet clearly defined. Although the potential 
mechanisms mediating RIC are often divided into three separate 
categories, it is important to note that these three pathways may 
interact or overlap, and are not mutually exclusive.
Clinical question II: Should RIC be used to improve 
functional outcomes in patients with acute ischemic 
stroke? 
Background. Acute ischemic stroke is caused by occlusion of a 
cerebral artery; therefore, timely recanalization of the occluded 
artery and reperfusion of salvageable ischemic brain tissue are 
the most effective maneuvers for salvaging tissue that is not 
already infarcted (Rha and Saver, 2007; Prabhakaran et al., 
2015). Currently, intravenous thrombolysis and endovascular 
thrombectomy are standard strategies for recanalization 
therapy. However, only a small proportion of acute ischemic 
stroke patients with large-vessel occlusion actually receive 
thrombectomy (approximately 10%, even in the USA) 
(McMeekin et al., 2017; Rai et al., 2017; Rocha and Jovin, 
2017). Even worse, with these therapies, therapeutic effects are 
far from satisfactory (Campbell et al., 2015; Fisher and Saver, 
2015; Goyal et al., 2015; Jovin et al., 2015; Saver et al., 2015; 
Goyal et al., 2016; Zhao et al., 2017a; Zhao et al., 2018d). Thus, 
there still remains ample room for improvement in patients with 
acute ischemic stroke, and alternative or adjunctive therapeutic 
strategies are urgently needed.
Summary of Evidence. The literature search revealed four 
published studies, one recently completed study, and one 
systematic review pertinent to this clinical question (Table 
1). One study assessed RIC in acute ischemic stroke patients 
treated with intravenous thrombolysis, one study assessed 
RIC in acute stroke patients treated with reperfusion therapy, 
another assessed the safety and feasibility of RIC in patients 
treated with thrombectomy, and two other studies assessed RIC 
in patients with acute ischemic stroke who did not receive any 
reperfusion therapies.
A Phase I study named REVISE-1 assessed the safety and 
feasibility of RIC in patients with anterior circulation stroke 
who were treated with endovascular thrombectomy within 
six hours of ictus (Zhao et al., 2018c). Twenty patients were 
recruited and underwent RIC pre- and post-thrombectomy, and 
then once daily for 7 consecutive days. RIC was well tolerated 
and feasible in this patient population; it exerted no significant 
influence on vital signs (i.e., blood pressure and heart rate), 
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intracranial pressure, cranial prefusion pressure, or the peak 
velocity of the middle cerebral artery. 
A proof-of-concept randomized controlled trial (RCT) 
investigated the impact of prehospital RIC as adjunctive 
therapy for acute ischemic stroke patients (≥ 18 years old) who 
were candidates to receive intravenous thrombolysis within 
4.5 hours of symptom onset (Hougaard et al., 2013; Hougaard 
et al., 2014). Four cycles of RIC stimulation were performed 
by the ambulance staff during transportation and, if not 
completed, the procedure was discontinued upon arrival at the 
stroke unit. Among the patients with confirmed acute ischemic 
stroke who received intravenous thrombolysis, there was no 
difference between the RIC (n = 91) and the control (n = 80) 
groups, with respect to penumbral salvage, final infarct size, 
infarct growth over baseline, or clinical outcomes at 3 months. 
However, in patients treated with RIC, a large proportion of the 
hypoperfusion area clearly displayed a lower risk of infarction 
at 1 month when compared with the controls (likelihood ratio 
test P = 0.0003).
Another RCT named RECAST-1 assessed the safety and 
primary efficacy of RIC in patients with acute ischemic stroke 
within 24 hours of ictus (England et al., 2017). Twenty-
Table 1. Remote ischemic conditioning (RIC) in patients with cerebrovascular disease.
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six patients with acute ischemic stroke were recruited and 
allocated to receive four cycles of RIC stimulus or sham RIC 
stimulus in the nonparetic arm. RIC was safe and feasible in 
this patient population, and 90-day National Institutes of Health 
Stroke Scale (NIHSS) scores were significantly lower in those 
receiving RIC (median 1 [interquartile range, 0.5-5] versus 
median 3 [interquartile range, 2-9.5], P = 0.04). 
One study assessed RIC in patients with acute ischemic 
stroke within 72 hours of ictus. Sixty patients were recruited 
and divided into two groups receiving either RIC or sham 
RIC up to day 14 (Li et al., 2018). At the 3-month follow-up 
appointment, RIC elicited a significant decrease in the NIHSS 
score and a 31.3% decrease in infarct volumes compared with 
the sham RIC control group (p < 0.05).
The recently completed REmote iSchemic Conditioning 
in acUtE BRAin INfarction Study (RESCUE-BRAIN) failed 
to demonstrate any benefit with lower limb RIC in terms of 
reducing cerebral infarct size at 24 hours (on MRI diffusion 
weighted imaging) in patients presenting with an acute 
ischemic stroke and treated by thrombolysis (ClinicalTrials.gov 
Identifier: NCT02189928). No benefits were observed with RIC 
on secondary functional endpoints including NIHSS scores at 
24 hours, and modified Rankin Scale (mRS) scores at 90 days.
In the meta-analysis of RIC for ischemic stroke (Zhao et 
al., 2018b), studies of patients with acute ischemic stroke were 
also included. However, the results showed that, for patients 
with acute ischemic stroke, there was no significant difference 
between RIC and non-RIC groups in stroke severity, as assessed 
by the NIHSS score and the final infarct volume (standardised 
mean difference (SMD) -0.24 mL, 95% CI -1.02 to 0.54).
Panel Recommendations.
In patients with acute ischemic stroke, RIC can be considered 
in those not receiving reperfusion therapy, however, currently 
available evidence suggests that RIC should not be used as 
routine adjunctive therapy in those receiving reperfusion 
therapy (conditional recommendation, low confidence in 
estimate of effects; see E-Table A1 and E-Table B1 in the 
Online Supplement). 
Discussion.
Justification. Among these five clinical studies, two studies 
showed RIC could improve functional outcome 90 days 
later in acute ischemic stroke patients that did not receive 
reperfusion therapy, therefore, RIC can be considered to 
improve neurological outcomes in those patients. Three clinical 
trials employed RIC in acute stroke patients that were treated 
with reperfusion therapy, but all three studies failed to prove 
the safety and efficacy profile of RIC under these conditions. 
Application of RIC as adjunctive therapy in acute ischemic 
stroke patient receiving reperfusion appears to be too early. 
Future studies. Although remote ischemic perconditioning 
during transportation to the hospital may preserve salvageable 
tissue for reperfusion therapy (Hougaard et al., 2014), if the 
occluded arteries are not eventually recanalized, the salvaged 
cerebral tissue will likely succumb to infarct. Therefore, 
acute ischemic stroke patients receiving endovascular 
therapy might be optimal candidates for investigations of the 
neuroprotective effects of RIC, as they can achieve a higher rate 
of recanalization (60-90%). Zhao and colleagues (2018c) have 
demonstrated the safety and feasibility of RIC in patients treated 
with thrombectomy, but this study recruited only 20 patents and 
did not examine the occurrence of hemorrhagic transformation. 
In addition, two studies showed RIC could improve functional 
outcomes in patients not receiving reperfusion therapy, however 
these two studies only recruited a small sample size and the 
power was low. Therefore, larger efficacy trials are warranted 
to determine both the safety profiles and efficacy against acute 
ischemic stroke in patients with or without reperfusion therapy. 
Furthermore, the benefits of RIC against cerebral infarct volume 
should be confirmed.
Clinical question III: Should RIC be used to reduce 
recurrent cerebrovascular events in patients with 
symptomatic intracranial atherosclerosis?
Background. Intracranial atherosclerosis is one of the leading 
causes of ischemic stroke worldwide, especially among people 
of Asian, African, and Hispanic descent (Gorelick et al., 2008; 
Qureshi and Caplan, 2014; Ritz et al., 2014). In China and other 
Asian countries, intracranial atherosclerotic stenosis accounts 
for 33% to 67% of strokes or transient ischemic strokes (Huang 
et al., 1997; Wong et al., 2000; Lee et al., 2003; De Silva et al., 
2007). Even worse, intracranial atherosclerotic stenosis is also 
associated with an increased risk of recurrent stroke (Gorelick 
et al., 2008). Currently, the optimal management of intracranial 
atherosclerosis is based on a combination of antiplatelet 
drugs and cerebrovascular risk factor controls (Kernan et 
al., 2014). However, the annual risk of recurrent ischemic 
stroke and transient ischemic attack is still unacceptably high, 
ranging from 6% to 18%, depending on the patient population 
(Chimowitz et al., 2005; Chimowitz et al., 2011; Wang et al., 
2013; Amarenco et al., 2016; Park et al., 2017). Thus, the 
management of patients with intracranial atherosclerosis is still 
far from satisfactory, and new therapies are urgently needed to 
reduce recurrent strokes and improve patient prognosis. 
Summary of Evidence. The search strategy commissioned to 
answer this question uncovered a systematic review, a small 
pilot prospective cohort study, and two small RCTs (Table 1). 
Li et al. (2015) recruited 10 patients with unilateral middle 
cerebral artery stenosis and 24 healthy volunteers to assess 
the safety and feasibility of RIC in patients with intracranial 
atherosclerosis. RIC was safe and well tolerated in patients 
with intracranial atherosclerosis, and it exerted no significant 
influence on heart rate, oxygenation index, or mean flow 
velocity. 
Meng et al. (2012) conducted two RCTs to assess the 
benefits of RIC in intracranial atherosclerosis patients who 
were at or below 80 years of age, or above 80, respectively. In 
one RCT, 103 patients aged 18 -80 years who had suffered a 
stroke or transient ischemic attack within the previous 30 days 
were recruited and allocated to two groups (intervention = 51 
patients; control = 52 patients) (Meng et al., 2012). Patients in 
the intervention group underwent additional RIC twice daily 
for 300 consecutive days. Sixty-eight patients completed the 
study, and the incidences of recurrent stroke at 90 and 300 days 
were only 5% and 7.9% in the RIC group (n = 38), but 23.3% 
and 26.7% in the control group (n = 30). Importantly, RIC also 
improved recovery from the initial stroke, as measured by 90-
day mRS scores of 0-1 (65.8% versus 13.3%, p < 0.001). The 
ratios of improved cerebral perfusion, as measured by single 
photon emission computed tomography, were 31.6% versus 
6.7% at day 90 (p = 0.012) and 76.3% versus 53.3% at day 300 
(p < 0.01).
In the second RCT study, Meng and colleagues (2012) 
recruited 79 patients aged 80-95 years old with ischemic 
stroke or TIA within the previous 7 days (intervention = 40; 
control = 39). Patients received either RIC or sham RIC for 180 
consecutive days. Fifty-eight patients completed the study (30 
in the RIC group and 28 in the sham group), and the recurrence 
of stroke and transient ischemic attack was 30% versus 67.8%, 
respectively (log-rank test, p = 0.004). Additionally, on day 180, 
the NIHSS scores were 2.97 ± 1.97 versus 4.82 ± 2.72 (p < 0.01) 
and the mRS scores were 1.4 ± 1.0 versus 2.3 ± 1.1 (p<0.01) in 
RIC versus sham groups. 
The meta-analysis of RIC for ischemic stroke included the 
REVIEW ARTICLE
Conditioning Medicine 2019 | www.conditionmed.org
Conditioning Medicine | 2019, 2(5):225-241
230
two aforementioned RCTs as well as studies of patients with 
intracranial atherosclerosis (Zhao et al., 2018b). The results 
revealed that recurrent stroke is significantly reduced by RIC 
in patients with symptomatic intracerebral atherosclerosis (RR 
0.32, 95% CI 0.12 to 0.83).
Panel Recommendations.
In patients with symptomatic intracranial atherosclerosis, long-
term repeated RIC can be used to prevent recurrent ischemic 
cerebrovascular events (conditional recommendation, low 
confidence in estimate of effects; see E-Table A2 and E-Table 
B2 in the Online Supplement).
Discussion
Justification. This recommendation was based mainly on two 
RCTs and the meta-analysis of their results. The two RCTs 
demonstrated that repeated RIC, applied consecutively after 
ischemic cerebrovascular events, could not only prevent 
the recurrence of ischemic cerebrovascular events, but also 
facilitate the recovery of neurological deficits. In addition, 
RIC is not only effective in patients aged 18 to 80 years, but 
also effective in elderly patients aged >80 years. Thus, if 
patients experience ischemic cerebrovascular events caused 
by intracranial atherosclerosis, RIC should be considered as 
a strategy to prevent recurrent cerebrovascular events and 
facilitate the recovery of the index neurological deficits.
Implementation considerations. As recurrent ischemic 
cerebrovascular events were much more frequent in the several 
days immediately after the index ischemic events (Wang et al., 
2013; Banerjee and Chimowitz, 2017), it is advisable to apply 
RIC as early as possible after the index event (within hours or 
days of the event). More importantly, repeated RIC should be 
applied consecutively for 180 to 300 days, or much longer.
Future studies. Although previous studies have demonstrated 
the safety and efficacy of RIC for patients with intracranial 
atherosclerosis, these studies recruited only a small number of 
patients and suffer from multiple methodological limitations 
(including per-protocol analyses and large numbers of patients 
lost during follow up). Therefore, much more powerful studies 
with large sample sizes are urgently needed to verify these 
important results. In addition, all participants recruited to 
clinical trials appear to display good compliance to the RIC 
regimen, although the daily use of RIC may not be executed 
successfully for all patients in real clinical practice. Therefore, 
it is worth investigating whether the use of RIC every 3 days, 7 
days, or much longer periods is also effective.
Clinical question IV: Should RIC be used to improve 
neurological outcomes in patients with cerebral small vessel 
disease?
Background. Cerebral small vessel disease is responsible for 
approximately 25% of all ischemic strokes. It causes damage 
to deep cerebral grey and white matter, which can be detected 
using brain imaging as leukoaraiosis, small subcortical infarcts, 
and microbleeds (Bamford et al., 1987; Petty et al., 2000; 
Wardlaw et al., 2013a; Wardlaw et al., 2013b; Zwanenburg 
and van Osch, 2017). More than half of all elderly people 
display cerebral leukoaraiosis, as it is estimated to range from 
70-80% in people over 60 years (Liao et al., 1997; de Leeuw 
et al., 2001; Schmidt et al., 2011). Although strokes caused 
by cerebral small vascular disease are less severe in terms of 
their clinical outcome during the acute phase and short-term 
prognosis (Sacco et al., 1991; Kolominsky-Rabas et al., 2001), 
the long-term outcome of these patients is not benign, and is 
associated with functional impairments, cognitive decline, and 
mortality (Norrving, 2008; Pinter et al., 2015).
Summary of Evidence. The search strategy for this question 
yielded two small RCTs encompassing 53 participants (Table 
1). Both studies compared one year of RIC with sham RIC. 
One study recruited 17 patients with cerebral small vascular 
disease and randomly allocated them to the RIC group (n = 
9) or sham group (n = 8) (Mi et al., 2016). Patients received 
medical management and RIC or sham RIC twice daily for 
one year. The mean flow velocity of the middle cerebral artery 
(evaluated by transcranial Doppler) was accelerated (57.33 
[52.33-61.34] versus 51.33 [48.83-58.33], p = 0.038) and the 
post-treatment volume of the white matter lesions (evaluated by 
MRI) was reduced (4.19 [2.96-7.25] versus 6.06 [4.67-10.95], 
p = 0.050) after one year of RIC treatment, but there was no 
statistically significant difference between the two groups 
(p > 0.05 each). Another RCT assessed RIC in patients with 
cerebral small vessel disease-related mild cognitive impairment 
(Wang et al., 2017b). Thirty-six patients were recruited and 
randomly allocated to the RIC (n = 18) or sham group (n = 18). 
After one year of treatment, the white matter hyperintensity 
volume on MRI was significantly reduced by RIC compared 
to sham treatment (-2.632 ml versus -0.935 ml, P = 0.049) 
and visuospatial and executive abilities were also significantly 
improved (0.639 versus 0.191; P = 0.048). Changes of the 
pulsation indices of the middle cerebral arteries (evaluated 
by transcranial Doppler) from baseline to one year were 
significantly different between the two groups of patients (right 
side: -0.075 versus 0.043; P = 0.030; left side: -0.085 versus 
0.043; P = 0.010). 
Panel Recommendations.  
In patients with cerebral small vessel disease and those who 
suffer from cerebral small vessel disease-related cognitive 
impairment, there is insufficient data to recommend routine use 
of RIC as an adjunctive therapy (conditional recommendation, 
very low confidence in estimate of effects; E-Table A3 and 
E-Table B3).
Discussion 
Justification and implementation. These recommendations are 
based on two single-center RCTs that recruited a very small 
number of patients and in which the overall results for RIC in 
terms of cognitive function are neutral. Furthermore, the real 
benefits of RIC for patients with cerebral small vessel disease 
might be concealed due to the low power of the clinical study 
(e.g., small sample size) and large percentage of patients lost 
during follow up. As such further large adequately powered 
randomized controlled trials are needed. 
Future studies. 
Additional studies should be conducted to validate the 
published findings. Many key variables that could impact the 
results (including the management of blood pressure, glucose, 
and lipids) should be addressed rigorously in future studies. 
Additionally, it would be worth assessing the benefits of RIC 
for patients with vascular cognitive impairment, quite possibly 
the most common form of cognitive dysfunction (Roman et al., 
2004). “Vascular dementia” in its different forms shows times 
of stable cognitive function and sometimes even remissions, 
which is strikingly different to AD. Longer phases of stable 
cognitive function, and more frequent and more pronounced 
remissive phases could be a relevant endpoint in future studies 
as this is something one might expect from RIC.
Clinical question V: Should RIC be used to reduce 
perioperative complications in patients with carotid artery 
stenosis who are treated with carotid stenting?
Background. Currently, carotid artery stenting is one of the 
most common revascularization procedures to prevent ischemic 
cerebrovascular events (Benjamin et al., 2017). Several large-
scale trials have determined the benefits of carotid stenting 
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among patients with recent ischemic events as well as patients 
who are asymptomatic (Barnett et al., 1991; Hobson et al., 1993; 
Walker et al., 1995; European Carotid Trialists' Collaborative 
Group, 1998; Halliday et al., 2004; Bonati et al., 2015; 
Rosenfield et al., 2016). However, perioperative complications 
cannot be completely avoided. The rate of combined 30-day 
stroke and death ranges from 6% to 9% among symptomatic 
patients and from 2% to 4% among asymptomatic patients (Mas 
et al., 2006; Ringleb et al., 2006; Algra et al., 2010). In addition, 
previous studies found new cerebral ischemic lesions on post-
procedure MRI images in 20% to 70% of subjects undergoing 
carotid stenting (Heider et al., 2007; Kim et al., 2007; Lacroix 
et al., 2007; Bonati et al., 2010; Bijuklic et al., 2013). To make 
matters worse, these subclinical embolisms may have adverse 
effects on long-term cognitive function (Corea et al., 2001; 
Zhou et al., 2017).
Summary of Evidence. The search strategy for this question 
uncovered one RCT (Table 1) (Zhao et al., 2017b). The study 
recruited 189 patients with severe carotid artery atherosclerotic 
stenosis (70% - 99%) and allocated them to three groups (RIC, 
sham, and control groups). All patients received standard 
medical management, and patients in the treatment group 
received RIC twice daily for 2 weeks before the carotid stenting 
procedure. Finally, 162 patients completed carotid stenting 
and post-treatment MRI, and the incidence of new MRI brain 
lesions in the RIC group was 15.87%, lower than in the control 
group (41.27%; relative risk, 0.39; 96% confidence interval, 
0.21 – 0.82; p = 0.002) and the sham group (36.51%; relative 
risk, 0.44; 96% confidence interval, 0.20 – 0.91; p = 0.008). In 
addition, the average infarct volume was 0.03 mL (0.02 - 0.05), 
which was also significantly smaller than the 0.08 mL (0.06-
0.12) in the sham group and 0.07 mL (0.05-0.10) in the control 
group (p < 0.001 for each). 
Panel Recommendations
In patients with carotid artery stenosis who are treated 
with carotid stenting, two weeks of RIC treatment before 
the operation may be considered as a strategy to prevent 
perioperative complications (conditional recommendation, 
moderate confidence in estimate of effects; E-Table A4 and 
E-Table B4).
Discussion 
Justification and implementation. The RCT eligible for 
making this recommendation reported that two weeks of RIC 
before operation could significantly reduce the incidence of 
posttreatment brain lesion and infarct volume, and that the 
incidence of ischemic cerebrovascular events tends to be lower 
in the RIC group. Although RIC is associated with much higher 
rates of arm skin petechiae from repeated cuff applications, the 
adverse events are not serious and exert no harmful influence. 
Therefore, we suggest that two weeks of repeated RIC before 
the operation may be considered to reduce the perioperative 
complications for patients who will undergo carotid stenting. 
Future studies.
Much larger studies are needed to assess the benefits of 
RIC in preventing ischemic cerebrovascular events after 
carotid stenting. Furthermore, as the silent infarcts caused 
by microemboli have potential adverse effects on long-term 
cognitive function (Corea et al., 2001; Zhou et al., 2017), 
future studies should include a battery of long-term cognitive 
and psychological function tests in their outcome assessments. 
Additionally, postprocedural silent cerebral ischemic lesions 
are not an uncommon complication in many endovascular or 
vascular surgeries; therefore, it is also worth assessing whether 
RIC prevents silent cerebral embolisms during other medical 
procedures. 
Clinical question VI: Can RIC be performed safely to 
improve functional outcomes in patients with intracranial 
hemorrhage?
Background. Intracranial hemorrhage, a devastating disorder 
with poor prognosis and high mortality, can be classified 
into intracerebral hemorrhage, subarachnoid hemorrhage, 
and epidural and subdural hemorrhages (Naidech, 2011). 
Subarachnoid hemorrhage and intracerebral hemorrhage are life-
threatening conditions and represent the major, least-treatable 
subtypes. Subarachnoid hemorrhage has a high rate of death and 
complications, and 80% of cases are caused by the rupture of an 
intracranial aneurysm (van Gijn and Rinkel, 2001; Long et al., 
2017). The average mortality for subarachnoid hemorrhage is 
~51%, while 46% of survivors may suffer long-term cognitive 
impairments (Hop et al., 1997; Hackett and Anderson, 2000; 
Mayer et al., 2002). Although coil embolization and open 
surgery can be used to prevent the re-rupture of aneurysms, 
few therapies are available for the treatment of subarachnoid 
hemorrhage (Connolly et al., 2012). Intracerebral hemorrhage 
also has a poor prognosis; its 30-day mortality ranges from 35 
to 52% and its one-year functional independence rate ranges 
from 17 to 25% (van Asch et al., 2010; Poon et al., 2014; 
Moulin and Cordonnier, 2015). Unfortunately, clinical trials 
have failed to demonstrate the superiority of surgical hematoma 
evacuation and stereotactic or endoscopic clot aspiration over 
medical management (Mendelow et al., 2005; Gregson et al., 
2012). Thus, it remains an intractable condition and the least 
treatable form of stroke.
Summary of Evidence. The search strategy for this question 
found three studies on subarachnoid hemorrhage, including 
one Phase Ib study, one Phase I study, and one matched cohort 
study (Table 1). The Phase Ib study assessed the safety and 
feasibility of increasing durations of limb ischemia in patients 
with subarachnoid hemorrhage after endovascular coiling or 
surgical clipping therapy (Koch et al., 2011). In both of the 
lead-in and dose escalation phases, preconditioning procedures 
were well tolerated. No session was prematurely terminated due 
to subject discomfort, and no objective signs of neurovascular 
injury were observed. Another Phase I study assessed the safety 
and feasibility of lower-limb RIC for subarachnoid hemorrhage 
patients who were secured by endovascular coiling or surgical 
clipping (Gonzalez et al., 2014). The results showed that no 
patient developed deep venous thrombosis or injury, and no 
patients developed delayed ischemic neurological deficits. A 
matched cohort study, consisting of 21 RIC patients and 61 
matched controls, aimed to assess the potential benefits of 
lower-limb RIC for patients with aneurysmal subarachnoid 
hemorrhages (Laiwalla et al., 2016a). The latter study found 
that RIC was independently associated with good outcomes 
defined as mRS of 0 to 2 (odd ratio 5.17; 95% confidence 
interval 1.21 – 25.02). In addition, RIC elicited a trend toward 
lower incidences of stroke (28.6 versus 47.5 %) and death (4.8 
versus 19.7 %).
Panel Recommendations
In patients with aneurysm subarachnoid hemorrhage who have 
been treated with endovascular coiling or surgical clipping, 
there is insufficient evidence to recommend routine use of RIC 
as an adjunctive therapy (conditional recommendation, very 
low confidence in estimate of effects; E-Table A5 and E-Table 
B5).
Discussion
Justification. Currently there are only two case series and one 
matched cohort study, supporting a role of RIC in patients with 
aneurysm subarachnoid hemorrhage after endovascular coiling 
or surgical clipping, thus a RCT demonstrating efficacy is 
therefore needed. 
Future study. More recently, preclinical studies have found 
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that repeated RIC accelerates hematoma resolution and 
improves neurological outcomes after intracerebral hemorrhage 
(Geng et al., 2012; Vaibhav et al., 2018). As subarachnoid 
and intracerebral  hemorrhages share many common 
pathophysiological mechanisms, the safety, feasibility, and 
efficacy of RIC in patients with intracerebral hemorrhage needs 
to be investigated as soon as possible. Furthermore, a carefully 
conducted RCT is needed to determine whether RIC is effective 
in this setting.
Clinical question VII: Which cohorts of patients with 
cerebrovascular disease qualify for RIC treatment?
Background. Cerebrovascular diseases are divisible into 
ischemic and hemorrhagic cerebrovascular diseases, each of 
which also has several subtypes. Although the therapeutic 
treatments of each subtype have significantly improved during 
the past several decades, they are still unsatisfactory. Therefore, 
RIC has been investigated as an adjunctive therapy (i.e., both 
prevention and treatment) for improving the outcomes of 
cerebrovascular disease.
Summary of Evidence. The answers to this clinical question 
derive from the aforementioned historical studies (Table 1) 
and one systematic review that specifically investigated RIC 
for the management of ischemic stroke. Two pilot RCTs 
assessed the safety and preliminary efficacy of RIC in patients 
with acute ischemic stroke who did not receive thrombolysis 
or thrombectomy (England et al., 2017; Li et al., 2018). One 
prospective study specifically assessed the safety and feasibility 
of RIC in acute ischemic stroke patients with large artery 
occlusions treated with thrombectomy (Zhao et al., 2018c). One 
RCT specifically assessed the safety and efficacy of prehospital 
RIC in the treatment of acute ischemic stroke patients who 
were also candidates for intravenous thrombolysis (Hougaard 
et al., 2014). One recently completed trials assessed RIC in 
patients treated with intravenous thrombolysis or endovascular 
thrombectomy. One RCT assessed the safety and efficacy of 
pre-procedural RIC for the treatment of severe carotid artery 
stenosis patients who were treated with carotid stenting (Zhao et 
al., 2017b). Two small RCTs assessed the efficacy of long-term 
RIC for the treatment of cerebral small vessel disease (Mi et al., 
2016; Wang et al., 2017b). One observational study assessed 
the feasibility and safety of RIC in patients with unilateral 
middle cerebral artery stenosis and compared the data to 
healthy volunteers. Thereafter, two RCTs specifically assessed 
the efficacy of RIC in patients with symptomatic intracranial 
atherosclerosis (Meng et al., 2012; Li et al., 2015; Meng et 
al., 2015). One Phase I study and one Phase Ib study assessed 
the safety and feasibility of RIC in patients with aneurysm 
subarachnoid hemorrhage, after coiling or surgical clipping of 
the aneurysm (Koch et al., 2011; Gonzalez et al., 2014), and 
another matched cohort study evaluated the efficacy of RIC in 
this patient population (Laiwalla et al., 2016b).
Several study protocols have been published: one ongoing 
study is investigating RIC in patients with Moyamoya disease 
(Li et al., 2017), while another ongoing study is investigating 
RIC in patients with minor ischemic stroke or transient ischemia 
attack (Liu et al., 2018). A third multicenter trial is currently 
investigating RIC in patients with symptomatic intracranial 
atherosclerosis (Hou et al., 2016). Besides the aforementioned 
published studies and study protocols, the prevention of 
ischemic stroke with RIC was assessed non-specifically for 
the protection of other organs during operations, such as 
percutaneous coronary intervention (Hoole et al., 2009; Davies 
et al., 2013; Sloth et al., 2014; Elbadawi et al., 2017), coronary 
artery bypass grafting (Hausenloy et al., 2015; Meybohm et al., 
2015; Benstoem et al., 2017), and cardiac surgery and peripheral 
vascular surgery (Desai et al., 2011; Twine et al., 2014; Zarbock 
et al., 2015; Garcia et al., 2016; Lotfi et al., 2016; Cho et al., 
2017; Kahlert et al., 2017; Pierce et al., 2017).
Panel Recommendations. This section simply lists a narrative 
review of the application of RIC for cerebrovascular disease 
management as a paucity of research data in this area precludes 
the development of meaningful recommendations at this time.
Discussion. RIC has been widely investigated in clinical 
studies for the prevention and treatment of cerebrovascular 
disease, particularly the ischemic type. Clinical studies have 
demonstrated the benefits of RIC in patients with acute 
ischemic stroke, intracranial atherosclerosis, cerebral small 
vessel disease, and carotid artery stenosis patients treated with 
stenting. During some surgeries, the prevention of ischemic 
stroke by RIC was also investigated non-specifically. Although 
RIC has been investigated in patients with intracranial 
hemorrhage, only the aneurysm subarachnoid hemorrhage 
subtype was scrutinized. Thus, the safety and efficacy of RIC 
in patients with intracerebral hemorrhage urgently deserves to 
be investigated. Recently, repeated RIC was proposed to mimic 
the effects of regular exercise in healthy individuals (Zhao et 
al., 2018a). Due to its cost effectiveness, ease of use, and good 
safety profile, it would be worthwhile to explore the effects of 
RIC in preventing initial strokes, as well as the potential benefits 
of long-term repeated RIC treatment for cerebrovascular disease 
management. Additionally, investigating long-term repeated 
RIC in all-comer patients with cerebrovascular diseases would 
be an excellent new research goal.
Clinical question VIII: Which specific RIC protocols should 
be used in patients with cerebral vascular disease?
Background. RIC has been widely investigated in patients 
with cerebrovascular disease, but different studies used distinct 
RIC protocols (Zhao et al., 2019). The most commonly used 
protocols in clinical studies are four cycles of unilateral arm 
ischemia or five cycles of bilateral arm ischemia for 5 minutes, 
each followed by 5 minutes of reperfusion. The stimulus sites 
for RIC include the thigh and arm, and the duration of RIC 
treatment varies from once to twice daily for 12 months.
Summary of Evidence. The answers to this clinical question 
derive from previously published studies. The detailed protocols 
of RIC used in different studies are summarized in Table 1. 
Protocols of 4 × 5 minute inflations/deflations of the cuff on 
one arm were used in four studies of acute ischemic stroke; 5 
× 5 minutes of cuff inflations/deflations on bilateral arms were 
used in six studies (all these studies were conducted by the 
same study group from Xuanwu Hospital); and 4 × 5 minutes 
of cuff inflations/deflations on one leg were used in two studies 
of aneurysm subarachnoid hemorrhage. A cuff pressure of 200 
mmHg was most commonly used in previous studies, or 20 
and 25 mmHg (or much higher) above systolic pressure, until 
the pulse was abolished. The frequency of RIC varied most—
ranging from a single episode, once daily for 7 and 14 days, and 
twice daily for 2 weeks, 180 days, 300 days, or 1 year. 
Recommendations. For patients with cerebrovascular disease, 
we suggest selecting RIC protocols according to the protocols 
used in similar previous studies or their modifications. We 
also suggest that the arm(s) be used as the RIC stimulus site 
(conditional recommendation, panel experts’ consensus).
Discussion
Justification and implementation. No study specifically 
investigated RIC protocols in different patients with 
cerebrovascular disease. This recommendation was made 
based on a consensus of expert opinion, accounting for clinical 
experiences, and completed clinical trials. We recommend that 
the selection of RIC protocols be based on those previously 
REVIEW ARTICLE
Conditioning Medicine 2019 | www.conditionmed.org
Conditioning Medicine | 2019, 2(5):225-241
233
employed in successful clinical trials. In addition, as RIC is a 
non-invasive physical therapy and no serious adverse events 
have been reported, modifications of current RIC protocols 
(e.g., duration or number of RIC episodes) according to specific 
conditions are also worth considering. Although there may be 
no differences in RIC stimulation of the arm or leg, RIC of the 
leg may need much higher cuff pressure, cause more serious 
discomfort, and perhaps lead to deep venous thrombosis. 
Therefore, we recommend the arm(s) as a superior RIC stimulus 
site. 
Future studies. 
Current RIC protocols derive from the first experiment 
on ischemic preconditioning conducted over 30 years ago 
(Murry et al., 1986); however, the optimal RIC protocol is 
still undefined. Therefore, future studies should be performed 
to explore the optimal cycles, duration of ischemia, site of 
stimulus, and length of RIC for various types of cerebral 
vascular diseases.
Clinical question IX: What are the contradictions of RIC, 
and which parameters should be scrutinized to ensure the 
safety of RIC?
Background. As the limbs are easy to access even in intensive 
care wards and tolerate ischemia well, RIC is generally 
initiated in the limbs with several cycles of brief ischemia 
followed by reperfusion. Ischemia is usually initiated by a 
blood pressure cuff, so that the procedures are similar to blood 
pressure measurements, with the exception of the duration 
of the ischemia. Although RIC is relatively safe, a physical 
examination should be performed before the RIC procedure, 
and several contradictions (including soft tissue injury and 
orthopedic injury in the limbs, blood pressure >200 mm Hg, 
vessel occlusive comorbidities or venous thrombosis in limbs, 
etc.) may prevent its application.
Summary of Evidence. The answers to this clinical question 
derive from the completed clinical studies. Meng et al. (2012; 
2015) excluded patients with any soft tissue, orthopedic, and 
vascular injury of the extremities; those with hematologic 
disease and whose systolic blood pressure >200mmHg were 
also excluded. In another study, Meng et al. (2012; 2015) also 
excluded those with peripheral blood vessel disease (especially 
subclavian arterial stenosis). In Li’s study, healthy volunteers 
underwent psychiatric and medical evaluations, including 
physical examinations, body weight index measurements, blood 
tests, and electrocardiograms (Li et al., 2015). In patients with 
subarachnoid hemorrhage, Koch’s study excluded patients with 
a history of peripheral vascular disease and ankle brachial index 
<0.7, and those with any extremity soft tissue, orthopedic, or 
vascular injury, such as superficial wounds, cellulitis, fracture, 
deep vein thrombosis (Koch et al., 2011); those with a history 
of deep vein thrombosis, peripheral vascular disease, peripheral 
neuropathy were also excluded, as were those patients with 
new findings of these diseases upon physical examination 
(Gonzalez et al., 2014). In Wang’s study, patients with 
significant bleeding disorders, systolic blood pressure >200 
mm Hg with medication, any soft tissue or vascular injury, and 
any disease of the extremities that would contraindicate RIC 
were excluded (Wang et al., 2017b). Mi’s study also excluded 
patients with coagulative dysfunction (Mi et al., 2016). Zhao’s 
study excluded patients with uncontrolled hypertension (defined 
as systolic blood pressure ≥200 mm Hg despite medication 
usage at enrollment), any vascular, soft tissue, or orthopedic 
injury (e.g., superficial wounds and fractures of the arm), and 
peripheral vascular disease (especially subclavian arterial and 
upper limb artery stenosis or occlusion). In patients with acute 
ischemic stroke (including those treated with intravenous 
thrombolysis and endovascular therapy), no specific evaluation 
was performed.
Panel Recommendations. 
For patients who are candidates for RIC, we recommend that 
a physical examination and vascular ultrasound examination 
of the limb should be performed before any RIC procedures 
are initiated (conditional recommendation, panel experts’ 
consensus), provided the necessary equipment is available. 
Alternatively, stricter exclusion criteria are recommended if 
there are safety concerns that have not been clarified. In patients 
with traumatic or ischemic injuries and dysmelia that may 
hamper the procedures on the initiation tissue, we recommend 
that RIC not be used (conditional recommendation, panel 
experts’ consensus)
Discussion 
Justification. In the historical studies, no clinical examination 
before RIC procedures was put forward. The recommendations 
for this question were made based on a consensus of expert 
opinion according to exclusion criteria of the historical studies 
and clinical experiences. 
Implementation. We recommend that a physical examination 
should be performed for all RIC candidates. The physical 
examination should include measurements of blood pressure 
and bilateral radial and dorsalis pedis pulse, examinations of 
skin and soft tissue injuries of limbs, and identification of any 
dysmelia or any other abnormal conditions. The goals of the 
physical examination are to exclude those with any soft tissue 
injury, orthopedic injury in the limbs, and patients with blood 
pressure >200 mm Hg despite medication usage. Vascular 
ultrasound should be performed to detect any vessel occlusive 
comorbidities or venous thrombosis. Furthermore, in patients 
with a high risk of arterial occlusion or stenosis and with limb 
ischemia, the inspection should encompass venous thrombosis, 
arterial stenosis, plaques, and vessel abnormalities.
Clinical question X: What equipment should be chosen to 
perform the RIC procedures?
Background. The potential clinical value of RIC became clear 
after the discovery of the phenomenon by Przyklenk and her 
colleagues (Przyklenk et al., 1993). Since that publication, many 
clinical studies have been conducted using a variety of methods 
to induce RIC, including manual RIC with sphygmomanometers 
and automated devices. 
Summary of Evidence. The evidence consulted to answer this 
clinical question derives from historical clinical studies, and the 
methods used to induce RIC and its protocols are summarized in 
Table 1. The Xuanwu Hospital study group used an automated 
device (developed by Beijing Renqiao Cardio-Cerebrovascular 
Disease Prevention and Control Institution) to induce unilateral 
or bilateral arm RIC; both RIC and sham RIC devices were used 
in several of their studies (Meng et al., 2012; Hess et al., 2015; 
Li et al., 2015; Meng et al., 2015; Mi et al., 2016; Wang et al., 
2017b; Zhao et al., 2017b). In Li and England’s study of acute 
ischemic stroke patients, manual RIC was induced by using a 
standard upper arm blood pressure cuff (England et al., 2017). 
In Hougaard’s study, RIC was induced by using an automated 
device produced by CellAegis Devices Incorporated (Hougaard 
et al., 2014). In patients with subarachnoid hemorrhage, the 
authors also manually induced RIC with a standard blood 
pressure cuff (Koch et al., 2011; Gonzalez et al., 2014).
Panel Recommendations. 
We recommend that RIC procedures be performed by using 
automated devices or manual blood pressure cuffs (conditional 
recommendation, panel experts’ consensus).
Discussion 
Justification. Manual RIC using a standard blood pressure cuff 
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placed on arms or legs and inflated to 200 mmHg (or some 
degree of mmHg above systolic pressure) may be the simplest 
prototype of the RIC method. Currently, several companies 
have developed automated devices that are convenient for RIC 
applications. Theoretically, if done correctly, the effects of 
manual RIC should be the same as that induced by automatic 
devices. 
Implementation. In clinical practice, manual RIC is both 
impractical and costly, as it requires a dedicated individual to 
ensure that a specific algorithm of inflation/deflation cycles 
is applied over a treatment period of 40 minutes or more. An 
automated system is preferable, particularly for high-acuity 
populations (e.g., patients with acute ischemic stroke) who 
typically receive many treatments in several physical locations 
(ambulance, emergency department, and catheterization 
laboratory) over a very short period.
Future study. At least four start-up companies have undertaken 
the development of an automated RIC device (Garratt and 
Leschinsky, 2017). Two of the devices were used in patients 
with cerebrovascular disease. CellAegis Device, Inc, a 
Canadian company, developed a device, called autoRIC, which 
received market approval in Europe in 2012 and in Canada in 
2013 for the treatment of patients with ST-segment elevation 
myocardial infarction undergoing primary percutaneous 
coronary intervention. In China, a device called DoctorMate or 
XuanyiTong has been developed by Beijing Renqiao Cardio-
Cerebrovascular Disease Prevention and Control Institution. 
This device has been approved by the Chinese FDA, and 
received market approval in China in 2016 for the management 
of cerebrovascular disease. In the future, different automated 
RIC devices should be developed for distinct clinical settings, 
such as the ambulance, emergency department, operation room, 
ward, and home. For the application of chronic RIC, it would be 
important if the automated devices could come with compliance 
monitoring of the intervention.   
Clinical question XI: What adverse events occur in the 
aftermath of RIC?
Background. Distinct from pharmacotherapies, RIC is a 
physical therapy and can be induced with a standard blood 
pressure cuff. Therefore, RIC is less likely to interact with 
medications and impact the proper function of the liver and 
kidneys. However, the persistent occlusion of unilateral or 
bilateral limbs’ arteries for 5 minutes may be uncomfortable 
and influence hemodynamics, and repeated occlusion and 
reperfusion of arteries may also cause injuries to local tissue in 
the limbs.
Summary of Evidence. The answers to this clinical question 
derive from the historical clinical studies. Li’s study assessed 
the safety of RIC in healthy volunteers and patients with 
intracranial atherosclerosis; in both patients and heathy 
volunteers, RIC was well tolerated without any complications, 
and it had no significant influence on the tissue oxygenation 
Figure 1. Management of cerebrovascular disease patients with remote ischemic conditioning. RIC, remote ischemic conditioning; AIS, acute 
ischemic stroke; CSVD, cerebral small vessel disease; sICAS, symptomatic intracranial atherosclerosis; CAS, carotid artery stenting; SAH, 
subarachnoid hemorrhage. 
NOTE: RIC protocols are recommended based on current evidence, but the optimal RIC protocol remains undefined. Future studies may 
change the recommended RIC protocols.
*Physical examination includes measurements of blood pressure and bilateral radial and dorsalis pedis pulse, examinations of skin and soft 
tissue injuries of limbs, and detection of any dysmelia or any other abnormal conditions. 
**Vascular ultrasound examination refers to arterial and venous vessel of limbs; the inspection should encompass venous thrombosis, 
arterial stenosis, plaques, and vessel abnormalities. 
***Patients with SAH who will use RIC should be treated with coil embolization or open surgery.
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index of the ischemic forearm and brain, or the mean flow 
velocity of the middle cerebral arteries (Li et al., 2015). 
However, in healthy volunteers, there was a significant 
reduction in diastolic blood pressure (73.4 ± 7.6 mmHg versus 
68.3 ± 8.2mmHg; p = 0.031) and heart rate (73.5 ± 8.3 bpm 
versus 68.4 ± 9.1 bpm; p = 0.027) between baseline and 30 
minutes after completion of RIC procedures. In Meng’s study of 
patients with intracranial atherosclerosis, no local skin or vessel 
lesions were reported during the 300-day-long repeated pressure 
cuff applications (Meng et al., 2012). In Meng’s other study 
of RIC in octo- and nonagenarian patients, 16.7% complained 
of mild discomfort, but they tolerated the treatment. Transient 
sporadic petechiaes were observed in 3 cases during the first 
30 days of the study (Meng et al., 2015). No ecchymosis, 
tenderness to palpation, edema, skin breakage, or other skin 
lesions was observed. No deep vein thromboses were detected 
by vascular sonography during or at the end of the 180 days of 
RIC.
In Hougaard’s study of prehospital RIC, no RIC-related 
adverse events were reported (Hougaard et al., 2014). In 
England’s study of acute ischemic stroke patients within 24 
hours of ictus, there were no procedure-related serious adverse 
events and RIC did not significantly affect central blood 
pressure, mean arterial pressure, arterial compliance, Buckberg 
index, or the ipsilateral middle cerebral artery blood flow 
(England et al., 2017). In Li’s study of acute ischemic stroke 
patients within 72 hours of ictus, one patient displayed small 
subcutaneous bleeding at the cuff contact site, but no significant 
changes in blood pressure, mean velocity or pulsatility, and 
heart rate during repetitive RIC (Li et al., 2018). In patients with 
acute ischemic stroke treated with thrombectomy, Zhao et al. 
(2018c) found that no patient experienced serious RIC-related 
adverse events, and the intracranial pressure, cranial perfusion 
pressure, mean arterial pressure, heart rate, middle cerebral 
artery peak systolic flow velocity, and pulsatility index did not 
change significantly before, during, or after limb ischemia.
In Koch’s study of patients with subarachnoid hemorrhage, 
no objective signs of neurovascular injury were observed, 
and no subjects experienced skin breakdown, prolonged 
discoloration, or temperature or pulse disparities in the treated 
limb (Koch et al., 2011). Although deep vein thrombosis 
was found in three patients, only two were symptomatic, and 
included one in the RIC-undergoing arm and the other in the 
leg contralateral to the conditioned leg. Importantly, the author 
concluded that these were unrelated to the RIC intervention. In 
Gonzalez’s study of patients with subarachnoid hemorrhage, 
no patient developed symptomatic deep vein thrombosis, 
bruising, or injury related to the RIC procedure, and analyses 
of vital signs and additional monitoring data did not reveal any 
statistically significant change for any of the repeated measures 
analysis of variance treatments (Gonzalez et al., 2014).
In patients treated with carotid stenting, Zhao reported that 
the RIC procedure was completed with a high compliance rate 
(98.41%), but that six subjects experienced arm skin petechiae 
from repeated pressure cuff applications (Zhao et al., 2017b). 
No ecchymosis, tenderness to palpation, edema, skin breakage, 
or other skin lesions was observed. In patients with cerebral 
small vascular disease, Mi and Wang did not report any adverse 
events after RIC (Mi et al., 2016; Wang et al., 2017b).
Panel Recommendations. This section is only a narrative 
review of the clinical use of RIC for cerebrovascular disease 
management; therefore, no recommendations are needed.
Discussion
In patients with cerebrovascular disease, RIC was well 
tolerated, even when applied repeatedly for 1 year or in the in 
critically ill patient population. No RIC-related severe adverse 
events were reported. The most common adverse event was 
skin petechiae or light subcutaneous bleeding at the cuff contact 
site or the ischemic forearm; these adverse events do not seem 
to cause any harmful impacts and disappear within one or two 
weeks. Several studies have evaluated the influence of RIC on 
patients’ hemodynamics by using different methods in distinct 
patient population, and all the results are in agreement that 
RIC does not influence blood pressure, intracranial pressure, 
intracranial perfusion pressure, blood flow velocity of middle 
cerebral artery, or other parameters of hemodynamics. 
Therefore, RIC is distinct from external counterpulsation, which 
changes hemodynamics (Manchanda and Soran, 2007; Yang 
and Wu, 2013). Rather, RIC exerts its protective roles through 
other mechanisms, and has no significant influence on cerebral 
hemodynamics. However, one study of healthy volunteers 
found a significant reduction in diastolic blood pressure and 
heart rate after RIC. No other studies reported this phenomenon; 
thus, further investigations are needed to determine whether this 
phenomenon was caused by bias or by RIC itself. It is important 
to note that a Cochrane systematic review of RIC for preventing 
and treating ischemic stroke reported no severe adverse events 
related to RIC procedures (Zhao et al., 2018b). In patients with 
subarachnoid hemorrhage, one study reported that deep vein 
thrombosis was a concern. Although the authors asserted that 
this adverse event was unrelated to the RIC intervention, in 
high-risk patients of deep vein thrombosis, cautions should be 
exercised when using RIC.
Summary
These clinical practice guidelines represent our collective 
synthesis of the latest evidence on the utility of RIC for 
cerebrovascular disease management. The guidelines offer a 
number of clinical recommendations pertaining to each question 
posed by the panel (Figure 1). Although five recommendations 
were prepared based on previously published studies with 
rigorous methodologies and three recommendations were based 
on the consensus of expert opinion, it must be noted that some 
of the latter recommendations were based on a small number of 
low-power clinical studies. Thus, future higher-quality studies 
may shift the recommendations. 
Due to its non-invasive nature and excellent safety profile, 
the use of RIC offers promise in the broad clinical management 
of both ischemic and hemorrhagic cerebrovascular disease. 
However, more studies are urgently needed, including 
investigations of the precise underlying mechanisms and 
determination of optimal RIC protocols. Even more importantly, 
clinicians and investigators should exercise caution regarding 
patient discomfort, transient sporadic petechiaes, and other 
potential adverse events during the implementation of RIC. 
Finally, a battery of clinical examinations (e.g., physical 
examination and vascular ultrasound examination) is imperative 
before initiation of RIC procedures.
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